Predicting the outcomes of combination therapy in patients with chronic hepatitis C using artificial neural network.

ABSTRACT:

Background

Treatment with Peginterferon Alpha-2b plus Ribavirin is the current standard therapy for chronic hepatitis C (CHC). However, many host related and viral parameters are associated with different outcomes of combination therapy.

Objectives

The aim of this study was to develop an artificial neural network (ANN) model to predetermine individual responses to therapy based on patient's demographics and laboratory data.

Patients and methods

This case-control study was conducted in Tehran, Iran, on 139 patients divided into sustained virologic response (SVR) (n = 50), relapse (n = 50) and non-response (n = 39) groups according to their response to combination therapy for 48 weeks. The ANN was trained 300 times (epochs) using clinical data. To test the ANN performan

SUBMITTER: Sargolzaee Aval F 

PROVIDER: S-EPMC4071357 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature